A long-acting PAI-1 inhibitor reduces thrombus formation

• Published in: Thrombosis and haemostasis Vol. 117; no. 7; p. 1338
• Main Authors: Peng, Shuangzhou, Xue, Guangpu, Gong, Lihu, Fang, Chao, Chen, Jingfei, Yuan, Cai, Chen, Zhuo, Yao, Lishan, Furie, Bruce, Huang, Mingdong
• Format: Journal Article
• Language: English
• Published: Germany 2017
• Subjects: Animals; Bleeding Time; Disease Models, Animal; Drug Design; Fibrinolysis - drug effects; Fibrinolytic Agents - blood; Fibrinolytic Agents - chemistry; Fibrinolytic Agents - pharmacology; Half-Life; Humans; In Vitro Techniques; Mice; Mice, Inbred C57BL; Models, Molecular; Mutagenesis, Site-Directed; Peptide Fragments - pharmacology; Plasminogen Activator Inhibitor 1 - blood; Plasminogen Activator Inhibitor 1 - chemistry; Plasminogen Activator Inhibitor 1 - pharmacology; Protein Engineering; Recombinant Fusion Proteins - blood; Recombinant Fusion Proteins - chemistry; Recombinant Fusion Proteins - pharmacology; Serine Proteinase Inhibitors - blood; Serine Proteinase Inhibitors - chemistry; Serine Proteinase Inhibitors - pharmacology; Serpin E2 - antagonists & inhibitors; Thrombosis - prevention & control; Urokinase-Type Plasminogen Activator - pharmacology; thrombosis; PAI-1 inhibitor; human serum albumin (HSA); clot lysis

Plasminogen activator inhibitor 1 (PAI-1) is the main inhibitor of tissue-type and urokinase-type plasminogen activators (t/uPA) and plays an important role in fibrinolysis. Inhibition of PAI-1 activity prevents thrombosis and accelerates fibrinolysis, indicating that PAI-1 inhibitors may be used as...